Gland Pharma has received Establishment Inspection Report (EIR) from the USFDA indicating closure of the inspection. The company announced through an exchange filing.

Earlier on July 14, Grand pharma through an exchange filing informed that the USFDA has concluded a good manufacturing practices inspection at the company's Dundigal Facility at Hyderabad between July 3, 2023 to July 14, 2023.

The inspection that was completed was concluded with One (1) 483 Observation. The corrective and preventive actions for this observation will be submitted to the USFDA within the stipulated period and the observation issued is neither a repeated observation nor is it related to data integration.

Gland Pharma shares gained nearly 3 percent in trade after receiving EIR.